SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Intermediate follow-up) — Abraham Lincoln — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAbraham Lincoln
Date of birth1809-02-12
IdentifiersMRN HR-NI001-SYN-TD; SSN (made up) 000-01-6683
Document date1841-08-11
AuthorElena Marquez, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week depression treatment follow-up. [S]

History of Present Illness

Mr. Lincoln returns six weeks after starting sertraline 50 mg daily for a moderate depressive episode. His mood is brighter on most days, and he is enjoying his work again. He is back at court on his usual schedule and writes letters to friends two or three times a week. He falls asleep within half an hour and wakes once a night, compared with the broken sleep he described at intake, and his concentration on long briefs is better. Mild nausea in the first two weeks settled by the third week. He has had no headache, diarrhea, restlessness, or sexual side effects. He misses about one dose every two weeks. He has had no suicidal thoughts since the intake visit and still carries his safety plan. He drinks no alcohol. He saw Dr. Natarajan of psychiatry this morning. [S]

ElementDetail
Interval changeMood brighter on most days; back to court work and letters to friends
SleepAsleep within half an hour; wakes once a night
Medication toleranceNausea resolved by week three; no other adverse effects
AdherenceMisses about one dose every two weeks
SafetyNo suicidal thoughts since intake; safety plan carried
PHQ-99, down from 14

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; no weight change of note
GastrointestinalNegativeEarly nausea resolved; no diarrhea, heartburn, or bleeding
GenitourinaryNegativeNo sexual side effects
NeurologicalNegativeNo headache, tremor, or restlessness
PsychiatricPositiveLow mood easing but not gone; sleep and concentration better; no suicidal thoughts, elevated mood, or racing thoughts

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1841-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1841-08-11Body height193cmS
1841-08-11Body weight82.4kgS
1841-08-11Body mass index (BMI) [Ratio]22.1kg/m2S
1841-08-11Systolic blood pressure116mm[Hg]S
1841-08-11Diastolic blood pressure72mm[Hg]S
1841-08-11Heart rate70/minS
1841-08-11Respiratory rate14/minS
1841-08-11Body temperature36.8CelS
1841-08-11Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1841-08-11Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S

Physical Exam

Vital signs recorded on 1841-08-11; see the Vital Signs section. [S]

SystemFinding
GeneralTall, neatly dressed, comfortable, and engaged
Mental statusAlert and oriented; mood "better, not yet myself"; affect mildly constricted but brighter and reactive, with humor; thought process linear; no suicidal ideation or psychotic features; insight and judgment good
NeurologicalNo tremor; gait normal

Problems

ProblemClinical statusVerificationCodeProvenance
Major depressive disorder, single episode, moderate; synthetic modern diagnosis linked to documented low mood and its retrospective interpretationactiveprovisional F32.1S — Synthetic active diagnosis for the teaching episode; the historical depression label remains R.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today9, down from 14 at intake (36 percent): partial response, not yet the 50 percent reduction that defines response
SurveyPHQ-9 at four weeksAt least monthly during acute treatmentDeferredNot done: the care plan set the first review at six weeks, so no score was taken at four weeks, a deviation from the protocol. No harm resulted: today's score has fallen 5 points and he has no suicidal thoughts. Corrective action: a nurse telephone PHQ-9 in about four weeks, so the seven weeks to the twelve-week review are not left unmeasured
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the intake visit; PHQ-9 item 9 scored 0. Protective factors unchanged. Collaborative safety plan reviewed with him: he carries his copy and has 988 and the clinic number saved
Medication safetySertraline tolerability check two weeks after starting2 weeks after starting and after each dose changeDeferredNot done: no contact was scheduled between the intake visit and today, a deviation from the protocol, which also calls for closer contact in the first weeks of an antidepressant. No harm resulted judging by today's review: the mild nausea settled by the third week, and he has had no restlessness, agitation, or suicidal thoughts. Corrective action: a nurse telephone check one to two weeks after any future start or dose change is now in his plan
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayMisses about one dose every two weeks; nausea resolved; no headache, diarrhea, tremor, restlessness, sexual side effects, bruising, or bleeding
SurveyMood Disorder Questionnaire (bipolar screen)Once at the initial depression workupDeferredNot given at intake, a deviation from the protocol. Dr. Natarajan's interview today found no past periods of elevated or irritable mood, reduced need for sleep, or racing thoughts, so bipolar disorder is not suspected, and no harm resulted: he has had no activation on sertraline. The questionnaire will be used if hypomanic features appear
ExaminationWeight, BMI, and blood pressureBaseline metabolic review, then with each tolerability checkCompleted todayWeight 82.4 kg, up 0.4 kg since intake; BMI 22.1; blood pressure 116/72 mmHg
ExaminationMental status examinationEvery visitCompleted todayBrighter, reactive affect; linear thinking; no suicidal ideation or psychotic features
LaboratoryDrug levels and metabolic laboratory monitoringLithium, valproate, carbamazepine, or second-generation antipsychotic therapyNot indicatedSertraline monotherapy needs no routine laboratory monitoring
ExaminationAbnormal Involuntary Movement Scale (AIMS)Every 6 months on antipsychotic therapyNot indicatedNo antipsychotic medicine
ReferralPsychiatry consultationAt diagnosis, as the care plan specifiesCompleted todaySeen by Dr. Natarajan this morning. She agrees with the diagnosis and with sertraline monotherapy, found no bipolar or psychotic features, and judged acute suicide risk low
Self-managementBehavioral activation: two valued activities each weekEvery visitCompleted todayCourt work and letters to friends resumed; goal met

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse telephone check with a PHQ-9 in about four weeks. Twelve-week depression review in seven weeks. Call the clinic or 988 at any time if his mood worsens or suicidal thoughts appear. Next scheduled visit 1841-09-30: twelve-week depression care-plan review. [S]